thalidomide lipomed
lipomed gmbh - thalidomide - multiple myeloma - imunosupresivi - thalidomide lipomed in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy. thalidomide lipomed is prescribed and dispensed in accordance with the thalidomide lipomed pregnancy prevention programme (see section 4.
tecvayli
janssen-cilag international n.v. - teclistamab - multiple myeloma - antineoplastična sredstva - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
plerixafor accord
accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - immunostimulants, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.
talvey
janssen-cilag international n.v. - talquetamab - multiple myeloma - antineoplastična sredstva - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.
garamycin 80 mg/ml raztopina za injiciranje/infundiranje
krka, d.d., novo mesto - gentamicin - raztopina za injiciranje/infundiranje - gentamicin 120 mg / 1,5 ml - gentamicin
garamycin 40 mg/ml raztopina za injiciranje/infundiranje
krka, d.d., novo mesto - gentamicin - raztopina za injiciranje/infundiranje - gentamicin 80 mg / 2 ml - gentamicin
gentamicin krka 40 mg/ml raztopina za injiciranje ali infundiranje
krka, d.d., novo mesto - gentamicin - raztopina za injiciranje/infundiranje - gentamicin 40 mg / 1 ml - gentamicin
retafer 100 mg filmsko obložene tablete
krka, d.d., novo mesto - železo - filmsko obložena tableta - železo 100 mg / 1 tableta - železov(ii) sulfat
garamycin 1 mg/g mazilo
krka, d.d., novo mesto - gentamicin - mazilo - gentamicin 1 mg / 1 g - gentamicin
maxitrol 1 mg/3500 i.e./6000 i.e. v 1 ml kapljice za oko, suspenzija
novartis pharma gmbh - deksametazon; neomicinijev sulfat; polimiksinijev b sulfat - kapljice za oko, suspenzija - deksametazon 1 mg / 1 ml neomicinijev sulfat3500 mg / 1 ml polimiksinijev b sulfat6000 mg / 1 ml; neomicinijev sulfat 3500 mg / 1 ml polimiksinijev b sulfat6000 mg / 1 ml; polimiksinijev b sulfat 6000 mg / 1 ml - deksametazon in protimikrobne učinkovine